"One design for the LH trial is other/all “post viral syndromes”. Lyme disease was used as an example."

Can one of the mods or others enlighten me - does this mean that if a LH happens to have Lyme, and Vyro treatment for LH ends up curing their Lyme, that will be tracked?

Or does the above mean that if LH works, then they will somehow pivot this success into a Lyme & other "post viral syndromes" trials in a way that will save time & money for all those other indications?

I'm just not clear how LH can be an "all-in-one" design as the above seems to indicate.

Also, if anyone happens to catch the trial design once it's posted to clinicaltrials.gov or what-not...I'd be very curious if the endpoints will be subjective or objective...should be very interesting to see the design of this one.

Fwiw - the fact that NP specifically (somewhat) addressed the financing issue so quickly after many here, as I'm sure, emailed him & MM, lends confidence to me. He could have just let it be and dealt with it on the next public call, but he didn't, he made it a point to bring it up on a LH call when he could have easily not, and that comforts me, at least while I see how it all shakes out.